Steve N. Slilaty insider trades: Sunshine Biopharma (SBFM) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Steve reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 4, 2024 | SBFM | ↑ Buy | 100,000 | $0.10 | $10K | Direct | Mar 5, 2024 (1d) |
| Feb 8, 2024 | SBFM | ↑ Buy | 20,000 | $0.10 | $2K | Direct | Feb 12, 2024 (4d) |
| Apr 12, 2016 | SBFM | ↑ Buy | 253,082 | $0.20 | $50K | Owned by Advanomics Corporation, an enti | Apr 26, 2016 (14d) |
| May 27, 2015 | SBFM | ↑ Buy | 500,000 | $0.10 | $50K | Direct | Jun 1, 2015 (5d) |
| Sep 4, 2012 | SBFM | ↓ Sell | 2,591,500 | $0.05 | $130K | Owned by Advanomics Corporation, an enti | Sep 7, 2012 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Steve N. Slilaty's insider trades
Steve N. Slilaty is Chief Executive Officer at Sunshine Biopharma (SBFM). Since Sep 4, 2012, Steve has reported 4 open-market purchases worth $112K and 1 sale worth $130K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (9 filings), other transactions (4 filings), shares returned to the company (1 filing), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SBFM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.